--- title: "Synthetic securitisation in Japan — bank RWA relief via CLN / CDS on reference loan portfolios" aliases: - "Japan synthetic securitization" - "Credit-linked note Japan" - "Megabank RWA relief" - "SRT significant risk transfer Japan" - "Basel III RWA optimization Japan" - "FSA capital relief synthetic" - "structured-finance/synthetic-securitization-japan-bank-rwa-relief" domain: structured-finance created: 2026-05-25 last_updated: 2026-05-25 last_tended: 2026-05-25 review_by: 2026-11-25 confidence: likely tags: [structured-finance, synthetic, cln, cds, rwa, basel, bank, megabank, japan, srt, capital-relief] status: active sources: - "FSA capital-adequacy framework disclosures" - "Megabank IR / Pillar 3 disclosures (MUFG / SMFG / Mizuho)" - "BOJ Financial System Report" - "JCR / R&I credit-linked note rating commentaries" - "BIS Basel framework documentation" --- # Synthetic securitisation in Japan — bank RWA relief via CLN / CDS on reference loan portfolios ## TL;DR Synthetic securitisation — where a bank transfers credit risk on a reference loan portfolio to outside investors via a **credit-default swap (CDS)** or **credit-linked note (CLN)** structure without selling the underlying loans — is the modern Basel III tool for **risk-weighted asset (RWA) relief** on bank balance sheets. In Japan, the three megabanks ([[megabanks/mufg|MUFG]], [[megabanks/smfg|SMFG]], [[megabanks/mizuho-fg|Mizuho FG]]) have used synthetic securitisations selectively to free capital on **corporate-loan**, **project-finance**, and **infrastructure-finance** portfolios. Compared to European peer-bank deal flow, Japanese megabank synthetic-SRT (Significant Risk Transfer) issuance has been smaller and less frequent — Japanese banks historically have had ample capital buffers and have only intermittently needed RWA-relief deals. Investor base is dominated by global specialist credit-investor funds (hedge funds, structured-credit funds, some pension funds), which can absorb the junior or mezzanine risk-transfer tranches. [[structured-finance/credit-rating-methodology-jcr-r-and-i|FSA capital-relief approval]] requires the deal to demonstrate true credit-risk transfer under specific accounting and capital tests. ## Wiki route This entry sits under [[structured-finance/INDEX|structured-finance index]] as the **bank-capital-management** securitisation node. Read against [[structured-finance/japan-abs-market-overview|Japan ABS market overview]] (true-sale ABS as the alternative to synthetic), [[structured-finance/spv-tk-gk-vehicle-japan-tax|TK / GK SPV vehicle]] for the legal structure layer, and [[derivatives/japan-cds-market-overview|Japan CDS market overview]] for the underlying credit-derivative infrastructure. System frame: [[finance/INDEX|finance index]] for the broader bank-capital context, and institution anchors: [[megabanks/mufg|MUFG]], [[megabanks/smfg|SMFG]], [[megabanks/mizuho-fg|Mizuho FG]]. ## 1. The problem — bank capital constraints on loan growth Under Basel III rules, banks must hold regulatory capital against the credit risk of their loan book: - Corporate loans typically carry 50–100%+ risk-weight (varying by borrower rating) - Capital ratios (CET1, Tier 1, Total) set the maximum leverage - High-quality loans to lower-rated borrowers consume more capital than higher-rated borrowers For a megabank seeking to grow lending volume in a particular sector or geography (e.g., project-finance lending into infrastructure, leveraged-finance corporate loans, or trade finance into emerging markets), **the RWA constraint can bite before the funding constraint**. ## 2. The two paths to RWA relief | Path | Mechanism | Trade-off | |---|---|---| | **True-sale securitisation** | Sell the underlying loans to an SPV; loans leave the balance sheet | Customer-relationship implications; servicing handover; possible accounting/disclosure complexity | | **Synthetic securitisation** | Keep loans on balance sheet; transfer credit risk only via CDS / CLN | Customer relationship preserved; simpler operational handover; but capital relief depends on regulatory approval of risk transfer | For most large bank-customer relationships (where the bank wants to keep the relationship live for future lending, advisory, and cross-sell), synthetic securitisation is preferred — it relieves capital while preserving the customer-facing loan. ## 3. Synthetic securitisation structure ``` +---------------------------------+ | Originating bank | | - Holds reference loan | | portfolio on balance sheet | | - Pays protection premium | +----+----------------------+----+ | | CDS/CLN Capital relief protection (FSA-approved premium SRT) | v +----+----------------------------+ | Protection-selling SPV | | or direct investor | | - Funds collateral by issuing | | CLN tranches to investors | | - Bears reference-portfolio | | credit loss up to defined | | attachment point | +----+----------------------+----+ | | Junior tranche Senior tranche (first-loss to (higher loss investor) attachment) | | v v +----+-------+ +---------+--------+ |Specialist | |Pension / | |credit fund | |insurer / less | |(hedge fund)| |risk-tolerant inv | +------------+ +------------------+ ``` Key structural elements: - **Reference portfolio**: a defined pool of bank loans (e.g., 100–300 named corporate borrowers, or a portfolio of project-finance loans, or a thematic basket like trade-finance loans) - **Tranching**: typically a junior / first-loss tranche (most expensive protection but greatest capital-relief benefit), a mezzanine tranche, and a senior tranche (often retained by the bank or sold to lower-risk investors) - **Funded vs unfunded**: CLN is "funded" (investor pays cash up-front; SPV holds collateral); CDS can be "unfunded" (bilateral; counterparty-credit-risk considerations apply) - **Tenor**: typically 5–7 years matching average loan-portfolio life - **Reference obligations**: usually a static pool, sometimes a replenishable pool ## 4. FSA capital-relief approval — the structural test For the originating bank to count synthetic securitisation as **true risk transfer** (and thus take RWA reduction), the deal must satisfy regulatory tests: - Significant Risk Transfer (SRT) requirement — meaningful credit risk must have moved off the bank's balance sheet - The bank must not retain disproportionate retained tranche / first-loss - The protection seller (SPV / counterparty) must be reliable for the protection it sells - Accounting treatment must reflect the risk-transfer (or there must be specific Basel-allowed deconsolidation treatment) The FSA reviews each deal individually for SRT compliance. This is a meaningful structuring friction — deals that work in EU markets may need adjustment for Japanese approval. ## 5. Japanese megabank synthetic-SRT activity Japanese megabank synthetic-SRT issuance has been **smaller and less frequent** than European peer-bank flow: - European banks (BNP Paribas, Deutsche Bank, Santander, Crédit Agricole, Barclays, others) have been heavy users of synthetic-SRT for over a decade, with frequent multi-billion-euro deals - Japanese megabanks have used synthetic structures more selectively, partly because: - Capital ratios have been comfortably above regulatory minimums - Loan growth has been moderate, not requiring constant capital-relief deal flow - Cultural / relationship factors favour retaining loans visibly on the balance sheet - When megabanks have issued synthetic-SRT deals, the reference portfolios have tended to be **project-finance loans, infrastructure loans, leveraged-finance corporate loans, or specific geographic-exposure books** rather than core domestic-corporate lending The market has been growing in recent years as Basel finalisation (Basel III/IV, output floor) increases capital pressure even on well-capitalised banks. ## 6. Investor base The protection-seller side is dominated by: - **Specialist credit-investor funds** (hedge funds, structured-credit funds, dedicated SRT-investor funds) - **Pension funds and insurers** (some) for the more senior tranches - **Sovereign wealth funds** for selected large-ticket transactions - **Fund-of-funds** vehicles aggregating investor commitments Japanese investor base for synthetic-SRT is small — most investors are global firms with US / EU teams that book SRT transactions from offices in London, NY, or Hong Kong. ## 7. Comparison to true-sale ABS | Dimension | True-sale ABS | Synthetic securitisation | |---|---|---| | Loan ownership | Transferred to SPV | Retained by bank | | Customer relationship | Servicer-managed (often back to originating bank) | Fully retained | | Capital relief | Full (loan off balance sheet) | Partial (RWA reduction) | | Funding | Yes (cash from sale) | None (or partial via funded CLN structure) | | Operational complexity | Higher (loan transfer, servicer handover) | Lower (no loan transfer) | | Investor base | Banks, insurers, broad fixed-income | Specialist credit funds (often US / EU) | | Tax / accounting | True-sale accounting | Derivative-based accounting | | Typical use | Funding + capital | Capital-only | For pure RWA management on a relationship-sensitive corporate loan book, synthetic is the clear choice. For funding diversification on a granular consumer loan book, true-sale is the clear choice. ## 8. Recent illustrative themes (descriptive only) Without naming specific transactions, recent themes in Japanese megabank synthetic-securitisation issuance include: - **Project-finance and infrastructure-loan portfolios** — useful because these loans are large-ticket and capital-intensive - **Leveraged-finance corporate loan portfolios** — capital-intensive, with cyclical credit exposure that fund investors are willing to take - **Cross-border trade-finance portfolios** — often regulatory-capital-driven for political-risk-weighted lending - **ESG-linked variants** — emerging interest in structures tied to sustainability metrics The pace of new issuance has been increasing as Basel finalisation effective dates approach. ## 9. Counterpoints - **"Regulatory-capital arbitrage"** — Critics argue synthetic-SRT can be used to optimise reported capital ratios without materially changing the bank's risk profile if the retained portions and first-loss positions are structured to flatter regulatory ratios - **"Concentration in specialist investors"** — The SRT-investor base is small; if global SRT-investor capital tightens, Japanese megabanks may struggle to place new issuance economically - **"FSA approval friction"** — The case-by-case SRT-approval process creates execution uncertainty; deals can be re-structured during approval, affecting economics - **"Counterparty-credit risk on unfunded structures"** — Unfunded CDS structures expose the bank to credit risk on the protection-seller; funded CLN structures avoid this but require larger investor capital - **"Tail-risk transfer questioned"** — In severe credit stress, whether the SPV / fund counterparty can actually pay claims is a real concern; AIG-style protection-seller failure is the classic example - **"Limited public disclosure"** — Synthetic-SRT deals are often not publicly announced or are described in deliberately vague terms in Pillar 3 disclosures, making market analysis difficult ## 10. Open questions - The pace of Japanese megabank synthetic-SRT issuance under Basel finalisation pressure (output-floor effective dates, etc.) - Whether [[regional-banks/japan-post-bank|Japan Post Bank]] or large regional banks issue synthetic-SRT (so far the activity is concentrated in the megabanks) - Whether the FSA approval process becomes more standardised over time, reducing structuring friction - Whether Japanese institutional investors (life insurers, pension funds) develop appetite for the senior tranches of synthetic-SRT deals - The interaction between synthetic-SRT and [[structured-finance/aircraft-leasing-financing-japan-shosha|aircraft]] / [[structured-finance/ship-financing-japan-megabank|ship]] / [[structured-finance/project-finance-spv-japan-renewable|project-finance]] loan books — capital-intensive specialty loan portfolios are natural candidates - The treatment of ESG-linked synthetic-SRT structures and whether they gain regulatory or investor-demand traction ## Related - [[structured-finance/INDEX|structured-finance index]] - [[structured-finance/japan-abs-market-overview|Japan ABS market overview]] - [[structured-finance/spv-tk-gk-vehicle-japan-tax|TK / GK SPV vehicle]] - [[structured-finance/credit-rating-methodology-jcr-r-and-i|JCR / R&I methodology]] - [[structured-finance/abcp-conduit-japan-megabank|ABCP conduit]] - [[structured-finance/repackaging-note-japan|repackaging note]] - [[structured-finance/japan-clo-issuance-japanese-banks|Japan CLO investment]] - [[structured-finance/aircraft-leasing-financing-japan-shosha|aircraft leasing financing]] - [[structured-finance/ship-financing-japan-megabank|ship financing]] - [[structured-finance/project-finance-spv-japan-renewable|renewable project finance]] - [[structured-finance/infrastructure-finance-spv-japan|infrastructure finance SPV]] - [[structured-finance/npl-securitization-japan|NPL securitisation Japan]] - [[structured-finance/fitch-moody-sp-japan-criteria|Fitch/Moody's/S&P Japan criteria]] - [[derivatives/japan-cds-market-overview|Japan CDS market overview]] - [[finance/INDEX|finance index]] · [[finance/japan-leveraged-buyout-economics|Japan LBO economics]] - [[real-estate-finance/INDEX|real-estate-finance index]] - [[policy-finance/japan-project-finance-stack-diagram|Japan project finance stack]] - [[megabanks/mufg|MUFG]] · [[megabanks/smfg|SMFG]] · [[megabanks/mizuho-fg|Mizuho FG]] - [[cooperative-banks/norinchukin|Norinchukin]] · [[regional-banks/japan-post-bank|Japan Post Bank]] · [[financial-regulators/japan-exchange-group|JPX]] ## Sources - FSA capital-adequacy framework disclosures - Megabank IR / Pillar 3 disclosures — MUFG (https://www.mufg.jp/english/), SMFG (https://www.smfg.co.jp/english/), Mizuho FG (https://www.mizuho-fg.com/index.html) - BOJ Financial System Report — https://www.boj.or.jp/en/ - JCR / R&I credit-linked note rating commentaries - BIS Basel framework documentation — https://www.bis.org/ --- > [!info] 校核状态 > confidence: **likely**. Synthetic-SRT mechanics, Basel-rule requirements, and Japanese-megabank relative activity vs European peers are well-documented in BIS papers and bank IR disclosures. Specific Japanese-megabank transactions are abstracted because public disclosure is often deliberately vague at the deal level. The European-peer comparison is industry-standard discussion.